ATE386802T1 - Künstliche antikörperpolypeptide - Google Patents

Künstliche antikörperpolypeptide

Info

Publication number
ATE386802T1
ATE386802T1 AT98930131T AT98930131T ATE386802T1 AT E386802 T1 ATE386802 T1 AT E386802T1 AT 98930131 T AT98930131 T AT 98930131T AT 98930131 T AT98930131 T AT 98930131T AT E386802 T1 ATE386802 T1 AT E386802T1
Authority
AT
Austria
Prior art keywords
polypeptide
monobody
uncat
cat
identifying
Prior art date
Application number
AT98930131T
Other languages
English (en)
Inventor
Shohei Koide
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Application granted granted Critical
Publication of ATE386802T1 publication Critical patent/ATE386802T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98930131T 1997-06-12 1998-06-12 Künstliche antikörperpolypeptide ATE386802T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4941097P 1997-06-12 1997-06-12

Publications (1)

Publication Number Publication Date
ATE386802T1 true ATE386802T1 (de) 2008-03-15

Family

ID=21959681

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930131T ATE386802T1 (de) 1997-06-12 1998-06-12 Künstliche antikörperpolypeptide

Country Status (10)

Country Link
US (11) US6673901B2 (de)
EP (3) EP0985039B1 (de)
JP (1) JP3614866B2 (de)
AT (1) ATE386802T1 (de)
AU (1) AU729035B2 (de)
CA (1) CA2293632C (de)
DE (1) DE69839147T2 (de)
DK (1) DK0985039T3 (de)
ES (1) ES2301198T3 (de)
WO (1) WO1998056915A2 (de)

Families Citing this family (646)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE69941267D1 (de) * 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE19932688B4 (de) * 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2416219C (en) * 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
CA2418835A1 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
US7556925B2 (en) 2001-04-04 2009-07-07 University Of Rochester ανβ3 integrin-binding polypeptide monobodies and their use
EP1318195A1 (de) * 2001-12-10 2003-06-11 CatchMabs B.V. Ein Struktur für die Präsentation erwünschter Peptidsequenzen
US20030215914A1 (en) * 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
US20050037427A1 (en) * 2001-12-10 2005-02-17 Erwin Houtzager Structure for presenting desired peptide sequences
AU2003207459A1 (en) * 2002-01-03 2003-07-24 The Scripps Research Institute Cancer-associated epitope
AU2003209272A1 (en) * 2002-01-16 2003-09-02 Zyomyx, Inc. Engineered binding proteins
US6936427B2 (en) * 2002-02-08 2005-08-30 Trellis Bioscience, Inc. Real time detection of intermolecular interaction
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
EP1516186B1 (de) * 2002-06-26 2010-02-17 University Of Louisville Research Foundation, Inc. Verfahren zum apoptosenachweis
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
US7196715B2 (en) * 2003-01-17 2007-03-27 Hewlett-Packard Development Company, L.P. Speed control using drive current profile
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
WO2005023831A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Detection of cholesterol ozonation products
CA2537976A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Ozonation products of cholesterol for the treatment and prevention of artherosclerosis and/or cardiovascular diseases
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
ES2297673T3 (es) * 2004-03-03 2008-05-01 F. Hoffmann-La Roche Ag Metodo para la purificacion de un fragmento n-terminal del factor de crecimiento de hepatocitos.
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
DE102004049479A1 (de) * 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP2076614A4 (de) * 2006-10-16 2012-07-04 Univ Arizona Synthetische antikörper
ES2501947T3 (es) 2006-10-19 2014-10-02 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP1925664A1 (de) * 2006-11-15 2008-05-28 Scil proteins GmbH Künstliche Bindungsproteine auf Grundlage einer modifizierten alpha-Helix Region von Ubiquitin
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
NZ579594A (en) * 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CN101688200B (zh) * 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
EP2215246B1 (de) 2007-10-31 2015-01-07 MedImmune, LLC Proteingerüste
MX2010004761A (es) 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
US9885050B2 (en) 2007-11-08 2018-02-06 The University Of Chicago Molecular affinity clamp technology and uses thereof
AU2008322523B2 (en) 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
AU2008338464A1 (en) 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
EP2247615B1 (de) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Zielgerichtete therapeutika auf der basis von egfr gentechnisch hergestellten proteinen
JP2011518782A (ja) * 2008-04-10 2011-06-30 フジフィルム・マニュファクチュアリング・ヨーロッパ・ベスローテン・フエンノートシャップ ヘパリン結合部位および／またはヘパラン硫酸結合部位を富化した組換えタンパク質
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US8415291B2 (en) * 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
CN102596992B (zh) * 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
DK2464657T3 (en) 2009-08-10 2015-06-29 Morphosys Ag New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
US20120288507A1 (en) 2009-12-18 2012-11-15 Amgen Inc. Wise binding agents and epitopes
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
DK2528944T3 (en) 2010-01-29 2015-09-14 Morphosys Ag Rodent combinatorial antibody libraries
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
DK2558491T3 (en) * 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
KR20130056870A (ko) 2010-04-13 2013-05-30 메디뮨 엘엘씨 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드
EP2558106A1 (de) 2010-04-16 2013-02-20 Novartis AG Verfahren und zusammensetzungen für verbesserte implantateinheilung
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
HUE029622T2 (en) 2010-04-30 2017-03-28 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
EP2566499B1 (de) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP3023496B1 (de) 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
EP3091028A1 (de) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Auf fibronectin basierende gerüstproteine mit erhöhter stabilität
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2012008211A1 (en) 2010-07-14 2012-01-19 Genefrontier Corporation Rnf8-fha domain-modified protein and method of producing the same
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
ME02637B (de) 2010-08-20 2017-06-20 Novartis Ag Antikörper für den epidermalen wachstumsfaktorrezeptor 3 (her 3)
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2815416A1 (en) 2010-10-21 2012-04-26 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
CA2822684A1 (en) 2010-12-23 2012-06-28 Intercell Austria Ag Oprf/i agents and their use in hospitalized and other patients
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
EP3415528B1 (de) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc-fusionsproteine mit neuartigen linkern oder anordnungen
ES2823240T3 (es) 2011-04-19 2021-05-06 Amgen Inc Método para el tratamiento de la osteoporosis
US20140056912A1 (en) 2011-04-29 2014-02-27 Novartis Ag Methods of treating squamous cell carcinoma
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins
EP2714094B1 (de) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. An einen anti-nucleolin-wirkstoff konjugierte nanopartikel
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
DK2721152T3 (da) 2011-06-15 2019-07-01 Navigo Proteins Gmbh Dimere bindingsproteiner baseret på modificerede ubiquitiner
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
MX358827B (es) 2011-09-27 2018-09-05 Janssen Biotech Inc Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas.
KR102434073B1 (ko) 2011-10-11 2022-08-18 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
WO2013063391A2 (en) * 2011-10-28 2013-05-02 Trianni, Inc. Transgenic animals and methods of use
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CN103906533A (zh) 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP2788382A2 (de) 2011-12-05 2014-10-15 Novartis AG Antikörper für epidermalen wachstumsfaktor-rezeptor 3 (her3) gegen domäne ii von her3
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
KR20190120401A (ko) 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
CN104159922B (zh) 2012-01-10 2018-03-02 比奥根Ma公司 对转运治疗性分子穿过血脑屏障的增强
EP2814514B1 (de) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
CN104203280A (zh) 2012-03-27 2014-12-10 诺华股份有限公司 纤维化的治疗
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2657334B1 (de) 2012-04-26 2016-07-06 GeneFrontier Corporation Effizientes Verfahren zur Anzeige eines Proteinmultimers
US9441039B2 (en) 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2014039775A1 (en) 2012-09-07 2014-03-13 Rutgers, The State University Of New Jersey Hiv-1 antigens with discrete conformational forms of the v1/v2 domain and methods of use thereof
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
WO2014124017A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
US20160025749A1 (en) 2013-03-11 2016-01-28 Amgen Inc. Protein formulations
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
MX366978B (es) 2013-03-15 2019-08-01 Novartis Ag Conjugados de anticuerpo - farmaco.
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US10196446B2 (en) 2013-10-14 2019-02-05 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
WO2015073878A1 (en) 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
CN105934671B (zh) 2013-12-03 2019-04-19 哈佛大学董事会 用于评估妊娠糖尿病的方法和试剂
AU2014363987A1 (en) 2013-12-09 2016-06-30 Janssen Biotech, Inc. Compositions and methods for phagocyte delivery of anti-staphylococcal agents
CN103698175B (zh) * 2013-12-09 2016-06-22 成都欧林生物科技股份有限公司 金黄色葡萄球菌疫苗成品的解离及含量测定方法和检测试剂盒
WO2015095301A2 (en) 2013-12-17 2015-06-25 Irm Llc Cytotoxic peptides and conjugates thereof
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US20150174242A1 (en) 2013-12-19 2015-06-25 Mayo Foundation For Medical Education And Research Monovalent anti-cd3 adjuvants
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (de) 2014-01-21 2023-10-04 Novartis Ag Verbessertes antigen mit car-t-zellfähigkeit durch co-einführung von co-stimulatorischen molekülen
US20170073754A1 (en) 2014-02-07 2017-03-16 Novartis Ag Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
BR112016020065A2 (pt) 2014-03-12 2018-02-20 Novartis Ag sítios específicos para modificar anticorpos para fazer imunoconjugados
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
AU2015231170B2 (en) 2014-03-20 2019-10-03 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
US10590485B2 (en) 2014-05-29 2020-03-17 Geneticure Llc Therapeutic regimen for hypertension
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
US9884817B2 (en) 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
WO2015200027A1 (en) 2014-06-26 2015-12-30 Amgen Inc. Protein formulations
CA2954476C (en) 2014-07-10 2023-09-19 Novartis Ag Immune-stimulating monoclonal antibodies against human interleukin-2
US20170291956A1 (en) 2014-07-16 2017-10-12 David Livingston HER3 Inhibition in Low-grade Serous Ovarian Cancers
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
EP3779445A1 (de) 2014-08-01 2021-02-17 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Nachweis und behandlung von bovinem herpesvirus
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
EA201790336A1 (ru) 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2017001946A (es) 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
EP3180359A1 (de) 2014-08-14 2017-06-21 Novartis AG Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
EP3712171A1 (de) 2014-08-19 2020-09-23 Novartis AG Behandlung von krebs mit einem chimären cd123-antigenrezeptor
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP3215519A1 (de) 2014-11-06 2017-09-13 Novartis AG Amatoxinderivate und konjugate davon als inhibitoren der rna-polymerase
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
UY36401A (es) 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
EP3227446A1 (de) 2014-12-01 2017-10-11 Novartis AG Zusammensetzungen und verfahren zur diagnose und behandlung von prostatakrebs
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CN111018987B (zh) 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
RU2751362C2 (ru) 2014-12-29 2021-07-13 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
SMT202100688T1 (it) 2015-01-28 2022-01-10 Ra Pharmaceuticals Inc Modulatori di attività del complemento
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3253785B1 (de) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Neuartige egfr-bindende proteine
JP6862348B2 (ja) 2015-03-12 2021-04-21 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
HK1251488A1 (zh) 2015-05-05 2019-02-01 The University Of Louisville Research Foundation, Inc. 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂
JP7366518B2 (ja) 2015-05-06 2023-10-23 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン
SG11201707815RA (en) 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3302525A2 (de) 2015-06-05 2018-04-11 Novartis AG Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
JOP20160131B1 (ar) 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
DK3322721T3 (da) 2015-07-16 2022-03-14 Navigo Proteins Gmbh Nye immunglobulin-bindende proteiner og deres anvendelse i affinitetsoprensning
JP7105186B2 (ja) 2015-07-17 2022-07-22 ザ・ユニバーシティ・オブ・シカゴ 酵素を修飾するための方法および組成物
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
EP3331914A1 (de) 2015-08-03 2018-06-13 Novartis AG Verfahren zur behandlung von fgf21-vermittelten erkrankungen
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EP3842457A1 (de) 2015-09-09 2021-06-30 Novartis AG Moleküle zur bindung von thymus-stroma-lymphopoietin (tslp) und verfahren zur verwendung der moleküle
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
EP3353198B1 (de) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3-bindende fibronektin-basierte gerüstmoleküle
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
ES2987957T3 (es) 2015-11-23 2024-11-18 Novartis Ag Vectores de transferencia lentivirales optimizados y usos de los mismos
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
KR20260070290A (ko) 2015-12-16 2026-05-18 유씨비 홀딩스 인코포레이티드 보체 활성의 조절인자
TW201731872A (zh) 2015-12-18 2017-09-16 諾華公司 標靶CD32b之抗體及其使用方法
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
CA3009852A1 (en) 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20180099768A (ko) 2015-12-30 2018-09-05 노파르티스 아게 증진된 효능을 갖는 면역 이펙터 세포 요법
US11320422B2 (en) 2016-01-06 2022-05-03 Lonza Ltd. Inhibition of protein degradation for improved production
JP6993699B2 (ja) 2016-01-11 2022-02-03 ウニヴェルズィテート・ツューリヒ ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
CN108697733A (zh) 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
CA3014842A1 (en) 2016-02-19 2017-08-24 Morphosys Ag Antibodies for il-17c
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN108699551B (zh) 2016-03-04 2023-01-24 莫佛塞斯公司 多肽文库
KR102954104B1 (ko) 2016-03-10 2026-04-17 론자 리미티드 맞춤형 시설
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
ES3056995T3 (en) 2016-04-13 2026-02-25 Vivia Biotech Sl Ex vivo bite-activated t cells
KR102408260B1 (ko) 2016-04-14 2022-06-10 론자 리미티드 숙주 세포 단백질의 검출을 위한 조성물 및 방법
US20230071283A1 (en) 2016-04-15 2023-03-09 Aimee S. Payne Compositions and methods for selective protein expression
EP3442991A4 (de) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. Ras-bindende peptide und verfahren zur verwendung
KR102323872B1 (ko) 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
JP7103950B2 (ja) 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合性タンパク質及びその使用
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
WO2017191165A1 (en) 2016-05-03 2017-11-09 Lonza Ltd Modulation of lipid metabolism for protein production
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EA201892796A1 (ru) 2016-06-03 2019-06-28 Янссен Байотек, Инк. Связывающиеся с сывороточным альбумином домены фибронектина типа iii
CN109328197A (zh) 2016-06-07 2019-02-12 诺华股份有限公司 用于治疗具有补体c5多态性的患者的抗c5抗体
CA3026589A1 (en) 2016-06-10 2017-12-14 Lonza Ltd Method for stabilizing proteins
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
WO2017223180A2 (en) 2016-06-21 2017-12-28 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
EP3484455A2 (de) 2016-07-15 2019-05-22 Novartis AG Behandlung und prävention von zytokin-freisetzungssyndrom unter verwendung eines chimären antigenrezeptors in kombination mit einem kinasehemmer
KR20230100748A (ko) 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
SG11201900885VA (en) 2016-08-01 2019-02-27 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
IL307217B1 (en) 2016-08-02 2026-06-01 Lonza Ag Customizable facility
CN109562153A (zh) 2016-08-07 2019-04-02 诺华股份有限公司 mRNA介导的免疫方法
MA45921A (fr) 2016-08-08 2019-06-19 Amgen Inc Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
US11230576B2 (en) 2016-08-11 2022-01-25 Navigo Proteins Gmbh Alkaline stable immunoglobulin-binding proteins
CN109715199A (zh) 2016-09-14 2019-05-03 詹森生物科技公司 包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途
CA3036564A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
CN110121508A (zh) 2016-10-25 2019-08-13 法国国家健康和医学研究院 与cd160跨膜同种型结合的单克隆抗体
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
US10852271B2 (en) 2016-12-14 2020-12-01 Taiwan Semiconductor Manufacturing Co., Ltd. On-chip heater
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CN117653740A (zh) 2016-12-21 2024-03-08 诺华股份有限公司 用于消融造血干细胞的抗体药物缀合物
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
CN118320078A (zh) 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
EP3346001A1 (de) 2017-01-06 2018-07-11 TXCell Monospezifische regulatorische t-zellpopulation mit zytotoxizität gegenüber b-zellen
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
KR20190130608A (ko) 2017-03-22 2019-11-22 노파르티스 아게 면역종양학을 위한 조성물 및 방법
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
EP3612563A1 (de) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
WO2018195008A1 (en) 2017-04-21 2018-10-25 Mellitus, Llc Methods and antibodies for diabetes-related applications
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
EP3615068A1 (de) 2017-04-28 2020-03-04 Novartis AG Auf bcma abzielender wirkstoff und kombinationstherapie mit einem gamma-sekretase-inhibitor
EP3615055A1 (de) 2017-04-28 2020-03-04 Novartis AG Zellen, die einen auf bcma abzielenden chimären antigenrezeptor exprimieren, und kombinationsbehandlung mit einem gamma-sekretase-inhibitor
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP4328241A3 (de) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispezifische moleküle mit einer nichtimmunglobulin-heterodimerisierungsdomäne und verwendungen davon
EP3630836A1 (de) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
MX2019014450A (es) * 2017-05-31 2020-02-10 Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food Vacuna contra la enteritis necrotica en aves de corral.
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US11319371B2 (en) 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
US12054733B2 (en) 2017-06-16 2024-08-06 Lonza Ltd Universal self-regulating mammalian cell line platform for the production of biologics
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
DK3642227T3 (da) 2017-06-22 2024-09-02 Adivo Gmbh Hundeantistofbiblioteker
JP7280238B2 (ja) 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
WO2019017940A1 (en) 2017-07-19 2019-01-24 Rubius Therapeutics, Inc. COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASE
WO2019017937A1 (en) 2017-07-19 2019-01-24 Rubius Therapeutics, Inc. COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASE
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
US11814432B2 (en) 2017-09-20 2023-11-14 The University Of British Columbia Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
EP3459968A1 (de) 2017-09-20 2019-03-27 Numab Innovation AG Neuartige stabile antikörper mit variablen domänen-framework-kombinationen
EP3688031A1 (de) 2017-09-25 2020-08-05 MorphoSys AG Behandlung von atopischer dermatitis
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
IL273578B2 (en) 2017-10-10 2026-03-01 Numab Therapeutics AG Antibodies directed against PD-1 and methods of use thereof
EP3470428A1 (de) 2017-10-10 2019-04-17 Numab Innovation AG Anti cd137 antikörper und deren verwendung
CN111183159B (zh) 2017-10-10 2024-09-03 努玛治疗有限公司 靶向cd137的抗体及其使用方法
EP3470429A1 (de) 2017-10-10 2019-04-17 Numab Innovation AG Auf pdl1 gerichtete antikörper und verfahren zur verwendung davon
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
EP3713965A1 (de) 2017-11-22 2020-09-30 Novartis AG Reverse bindemittel für anti-faktor-xi/xia-antikörper und verwendungen davon
CN111417651B (zh) 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019147478A2 (en) 2018-01-18 2019-08-01 California Institute Of Technology Programmable protein circuits in living cells
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
US12077786B2 (en) 2018-02-02 2024-09-03 Lonza Ltd Methods of cell selection and modifying cell metabolism
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US11680091B2 (en) 2018-02-23 2023-06-20 The University Of Chicago Methods and composition involving thermophilic fibronectin type III (FN3) monobodies
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
EP3765517A1 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3774879B1 (de) 2018-03-30 2026-01-28 Amgen Inc. C-terminale antikörpervarianten
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
MX2020010808A (es) 2018-04-13 2021-03-02 Sangamo Therapeutics France Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210123016A1 (en) 2018-05-02 2021-04-29 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
EP3793596A1 (de) 2018-05-16 2021-03-24 MorphoSys AG Antikörper gegen glycoprotein vi
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CN119490583A (zh) 2018-05-31 2025-02-21 诺华股份有限公司 乙型肝炎抗体
JP7599205B2 (ja) 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
CN110655577A (zh) 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
UY38265A (es) 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN112384530B (zh) 2018-07-10 2024-02-06 国家医疗保健研究所 戊型肝炎病毒orf2i蛋白的表位肽
US20210324049A1 (en) 2018-07-10 2021-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for the orf2i protein of hepatitis e virus and uses thereof for diagnostic purposes
CN120174006A (zh) 2018-07-13 2025-06-20 隆萨有限公司 用于通过降低内源性蛋白质的水平来改善生物产物的生产的方法
WO2020028616A1 (en) 2018-08-02 2020-02-06 Lonza Ltd Methods for manufacturing recombinant protein comprising a disulfide bond
SG11202101415UA (en) 2018-08-10 2021-03-30 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
US11542305B2 (en) 2018-08-31 2023-01-03 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
US10955379B2 (en) 2018-09-27 2021-03-23 Taiwan Semiconductor Manufacturing Co., Ltd. Differential sensing with BioFET sensors
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
JP7592585B2 (ja) 2018-10-04 2024-12-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 粘膜炎症性疾患の処置のための方法及び医薬組成物
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (de) 2018-10-09 2020-04-15 Numab Therapeutics AG Auf cd137 gerichtete antikörper und verfahren zur verwendung davon
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP3873532A1 (de) 2018-10-31 2021-09-08 Novartis AG Dc-sign-antikörper-arzneimittelkonjugate
CN113348181A (zh) 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
AU2019387571A1 (en) 2018-11-30 2021-06-03 Celularity Inc. Placenta-derived allogeneic CAR-T cells and uses thereof
KR20210099614A (ko) 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
CA3121699A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
MX2021007047A (es) 2018-12-14 2021-10-26 Morphosys Ag Formulaciones de anticuerpos.
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
KR20210104106A (ko) 2018-12-18 2021-08-24 나피고 프로타인스 게엠베하 암 진단 및 치료를 위한 신규 folr1 특이적 결합 단백질
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
AU2019409132B2 (en) 2018-12-21 2026-08-06 Novartis Ag Antibodies to PMEL17 and conjugates thereof
CN111349550B (zh) * 2018-12-24 2022-12-23 中粮生物科技股份有限公司 一种高通量发酵好氧菌种的装置和方法以及他们的应用
WO2020146627A1 (en) 2019-01-10 2020-07-16 California Institute Of Technology A synthetic system for tunable thresholding of protein signals
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US12410260B2 (en) 2019-01-11 2025-09-09 The University Of North Carolina At Chapel Hill Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapy
EP3689907A1 (de) 2019-01-31 2020-08-05 Numab Therapeutics AG Auf il-17a gerichtete antikörper und verfahren zur verwendung davon
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
EP3927371A1 (de) 2019-02-22 2021-12-29 Novartis AG Kombinationstherapien von chimären egfrviii-antigenrezeptoren und pd-1-inhibitoren
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
US20220135658A1 (en) 2019-03-14 2022-05-05 Morphosys Ag Antibodies targeting c5ar
TWI924633B (zh) 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物
EP3942025A1 (de) 2019-03-21 2022-01-26 Novartis AG Car-t-zell-therapien mit erhöhter wirksamkeit
EP4332115A3 (de) 2019-04-03 2024-05-29 Precision Biosciences, Inc. Genetisch modifizierte immunzellen mit einer mikrorna-adaptierten shrna (shrnamir)
EP3947646A1 (de) 2019-04-05 2022-02-09 Precision BioSciences, Inc. Verfahren zur herstellung von populationen genetisch modifizierter immunzellen
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
JPWO2020213724A1 (de) 2019-04-19 2020-10-22
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
CN114072424A (zh) 2019-05-03 2022-02-18 莫佛塞斯公司 具有有限数量的nk细胞的患者中的抗cd19疗法
EP3966227A1 (de) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
CA3140063A1 (en) 2019-05-20 2020-11-26 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
ES2973767T3 (es) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
US20220273715A1 (en) 2019-07-25 2022-09-01 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
WO2021030303A1 (en) 2019-08-12 2021-02-18 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
WO2021035054A1 (en) 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
WO2021041177A1 (en) * 2019-08-23 2021-03-04 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating and preventing autoimmune induced cardiac long qt syndrome
US12460009B2 (en) 2019-09-04 2025-11-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Monoclonal antibodies specific for IL20-Rb, encoding nucleic acids thereof and methods of use thereof to treat bacterial-induced exacerbation of chronic obstructive pulmonary disease
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3800201A1 (de) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h-stimulierung verbessert nk-zellen-abtötungsaktivitäten
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
EP3808766A1 (de) 2019-10-15 2021-04-21 Sangamo Therapeutics France Interleukin-23-rezeptor-spezifischer chimärer antigen-rezeptor
US10984211B1 (en) 2019-10-18 2021-04-20 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device with bioFET and biometric sensors
US20220411479A1 (en) 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
WO2021084062A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
LT4051710T (lt) 2019-10-31 2026-03-10 Incyte Corporation Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
WO2021094461A1 (en) 2019-11-14 2021-05-20 Lonza Ltd Methods of cell selection
EP4061405A1 (de) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Impfstoffe auf der basis von mutantem calr und jak2 und deren verwendungen
JP7805928B2 (ja) 2019-11-26 2026-01-26 ノバルティス アーゲー Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
EP4069258A1 (de) 2019-12-04 2022-10-12 Celularity Inc. Aus der plazenta gewonnene, allogene car-t-zellen und verwendungen davon
US12162953B2 (en) 2019-12-06 2024-12-10 Yale University Enhanced targeting platform
EP4069285A1 (de) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methoden zur krebsimmuntherapie unter verwendung von lymphodepletionsregimen und allogenen cd19-, cd20- oder bcma-car-t-zellen
US20230020548A1 (en) 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
EP4072682A1 (de) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifität gegen her4 und verwendungen davon
US12351619B2 (en) 2019-12-18 2025-07-08 Aro Biotherapeutics Company Serum albumin-binding fibronectin type III domains and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4084821A4 (de) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. An cd33 bindende multifunktionsmoleküle und ihre verwendungen
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4104187A1 (de) 2020-02-14 2022-12-21 Novartis AG Verfahren zur vorhersage des ansprechens auf eine chimäre antigen-rezeptor-therapie
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
US12153043B2 (en) 2020-02-25 2024-11-26 Becton, Dickinson And Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
JP2023516008A (ja) 2020-02-27 2023-04-17 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
WO2021188599A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
US20230147657A1 (en) 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
CA3180222A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
EP4136228A4 (de) 2020-04-15 2024-09-11 California Institute of Technology Thermische kontrolle der t-zell-immuntherapie durch molekulare und physikalische betätigung
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
MX2022014203A (es) 2020-05-12 2023-02-22 Lyell Immunopharma Inc Espaciadores de receptores de antígenos quiméricos (car).
HRP20240979T1 (hr) 2020-05-19 2024-10-25 Les Laboratoires Servier Para-amino-benzil povezivači, postupak njihove pripreme i njihova upotreba u konjugatima
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
MX2022015586A (es) 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
EP4168449A1 (de) 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor-kombinationstherapie mit anti-cd19-antikörper und polypeptiden zur blockierung des angeborenen immuncheckpoints sirpa-cd47
EP4175664A2 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostata-neoantigene und ihre verwendungen
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CA3176556A1 (en) 2020-07-16 2022-01-20 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
EP3943097A1 (de) 2020-07-24 2022-01-26 AB2 Bio SA Car-t-zelltherapie
EP4192875A1 (de) 2020-08-10 2023-06-14 Precision BioSciences, Inc. Antikörper und fragmente spezifisch für b-zellreifungsantigen und verwendungen davon
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
JP7788106B2 (ja) * 2020-08-31 2025-12-18 国立大学法人東海国立大学機構 フィブロネクチンｉｉｉ型ドメイン骨格を含むポリペプチド
JP7851303B2 (ja) 2020-09-24 2026-04-24 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒトｃｄ３イプシロンに結合する新規なヒト抗体
US20230365995A1 (en) 2020-10-07 2023-11-16 Precision Biosciences, Inc. Lipid nanoparticle compositions
MX2023004299A (es) 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
US20250215081A1 (en) 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
AU2021377232A1 (en) 2020-11-10 2023-06-15 New York University Macropinocytosis selective monobody-drug conjugates
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
MX2023006010A (es) 2020-11-24 2023-06-08 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos.
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
AU2021391623A1 (en) 2020-12-04 2023-06-29 Incyte Corporation Anti-cd19 combination therapy
EP4259661A1 (de) 2020-12-14 2023-10-18 Novartis AG Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
KR20230157296A (ko) 2020-12-16 2023-11-16 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
WO2022171736A1 (en) 2021-02-10 2022-08-18 Limagrain Europe Multiplex targeted recombinations for trait introgression applications
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN115141276A (zh) 2021-03-31 2022-10-04 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
AU2022258829A1 (en) 2021-04-16 2023-10-26 Novartis Ag Antibody drug conjugates and methods for making thereof
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
EP4355352A1 (de) 2021-06-18 2024-04-24 advanceCOR GmbH Verwendung einer pharmazeutischen zusammensetzung
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN117642431B (zh) 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
AU2022318255A1 (en) 2021-07-27 2024-01-18 Morphosys Ag Combinations of antigen binding molecules
EP4388000A1 (de) 2021-08-20 2024-06-26 Novartis AG Verfahren zur herstellung eines chimären antigenrezeptorsexpression von zellen
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
WO2023072916A1 (en) 2021-10-27 2023-05-04 Granite Bio Ag Antibodies targeting ccr2
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
US20250001013A1 (en) 2021-11-24 2025-01-02 Novartis Ag Modulators of adeno-associated virus transduction and uses thereof
WO2023108150A1 (en) 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy
US20250382633A1 (en) 2021-12-21 2025-12-18 Universität Zürich Adenoviral vectors
EP4473010A1 (de) 2022-02-01 2024-12-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur diagnose von krankheiten im zusammenhang mit kollagenabbau
CA3251683A1 (en) 2022-02-18 2023-08-24 Adivo Gmbh FELINE ANTIBODY LIBRARIES
US20250163169A1 (en) 2022-02-25 2025-05-22 Institut National de la Santé et de la Recherche Médicale Antibodies for preventing the cleavage of cd95l by metalloproteases
EP4490187A4 (de) 2022-03-08 2026-02-25 Immunedge Inc Epo-rezeptor-agonisten und -antagonisten
JP2025510588A (ja) 2022-03-11 2025-04-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ細胞及びｔ細胞を特異的に初期化するための核酸系及びその使用
JP2025513714A (ja) 2022-03-22 2025-04-30 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃｄ３に特異的な脱免疫抗体
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
JP2025510997A (ja) 2022-03-30 2025-04-15 ノバルティス アーゲー 抗ナトリウム利尿ペプチド受容体１（ｎｐｒ１）抗体を使用して障害を治療する方法
JP2025512026A (ja) 2022-04-14 2025-04-16 ノバルティス アーゲー 抗ｃｄ１９剤の投与計画及びその使用
CA3255627A1 (en) 2022-05-06 2023-11-09 Novartis Ag NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
EP4525925A1 (de) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
US20250243263A1 (en) 2022-06-22 2025-07-31 Voyager Therapeutics, Inc. Tau binding compounds
EP4551601A1 (de) 2022-07-07 2025-05-14 Cimeio Therapeutics AG Antikörper gegen cd117
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
EP4581055A1 (de) 2022-08-31 2025-07-09 Universität Zürich In-situ-verabreichung bispezifischer t-zell-engager auf adenovirusbasis
EP4584291A1 (de) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antikörper mit spezifität gegen ltbp2 und verwendungen davon
AU2023337288A1 (en) 2022-09-08 2025-03-13 Gmax Biopharm Llc Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
KR20250067174A (ko) 2022-09-15 2025-05-14 노파르티스 아게 키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
EP4598945A1 (de) 2022-10-07 2025-08-13 Universität Zürich Parakriner adenoviraler transport von biomolekülen
KR20250093319A (ko) 2022-10-24 2025-06-24 에프. 호프만-라 로슈 아게 Il-6 길항제에 대한 반응 예측
WO2024099990A1 (en) 2022-11-07 2024-05-16 Leibniz-Institut Für Immuntherapie (Lit) TGF-ß SWITCH RECEPTOR CAR T CELLS
JP2025541618A (ja) 2022-11-28 2025-12-22 ノバルティス アーゲー Ｐｃｔａ誘導体、そのコンジュゲート及びその使用
JP2025541726A (ja) 2022-12-01 2025-12-23 ジェネレーション バイオ カンパニー 細胞標的化のためのステルス脂質ナノ粒子組成物
EP4637928A1 (de) 2022-12-23 2025-10-29 Cimeio Therapeutics AG Gegen cd45 gerichtete antikörper
IL321936A (en) 2023-01-05 2025-09-01 Prec Biosciences Inc Optimized engineered meganucleases with specificity for the human T-cell receptor alpha constant region gene
CN120513256B (zh) 2023-01-20 2026-07-10 迈威(美国)生物治疗有限公司 抗淀粉样蛋白β原纤丝/低聚物抗体和其用途
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
EP4676540A1 (de) 2023-03-10 2026-01-14 Novartis AG Panras-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
US20250011431A1 (en) 2023-03-27 2025-01-09 Adivo Gmbh Anti-canine pd-l1 antibodies
WO2024236167A1 (en) 2023-05-17 2024-11-21 Morphosys Ag Il-13 receptor alpha 2 binding polypeptides
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
CN121399160A (zh) 2023-05-29 2026-01-23 花岗岩生物股份公司 靶向ccr2的抗体
CN121443643A (zh) 2023-06-01 2026-01-30 皮埃尔法布雷医药公司 基于沉默抗体的抗met构建体用于治疗肿瘤和转移
WO2024261027A1 (en) 2023-06-19 2024-12-26 Vector Biopharma Ag Il-7-retargeting of adenoviruses for cell specific infection
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025061682A1 (en) 2023-09-21 2025-03-27 Universität Zürich Adenoviral targeting of dendritic cells
EP4784622A1 (de) 2023-09-28 2026-08-05 SixPeaks Bio AG Gegen actriia und actriib gerichtete antikörper
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
CN117503754B (zh) * 2023-11-07 2026-07-03 南开沧州渤海新区绿色化工研究有限公司 磺化硫桥偶氮杯芳烃及其与锰的配合物在清除活性氧中的应用
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
WO2025109043A2 (en) 2023-11-22 2025-05-30 Institut National de la Santé et de la Recherche Médicale Use of neutralizing anti-agr2 antibodies for preventing resistance to chemotherapy
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025129120A2 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
WO2025129085A1 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches in aav-based gene therapy
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025247917A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 AND ANTI-IFN-ω1 MONOCLONAL ANTIBODIES
WO2025247924A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247918A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247913A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Anti-ifn-omega1 monoclonal antibodies
WO2025250739A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg
WO2025259600A2 (en) 2024-06-10 2025-12-18 University Of Rochester Brain protein targets for the treatment of migraine
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026062585A1 (en) 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026062582A1 (en) 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026087699A1 (en) 2024-10-24 2026-04-30 Pierre Fabre Medicament New treatment of non-small cell lung cancer
WO2026132368A1 (en) 2024-12-20 2026-06-25 Veraxa Biotech Gmbh Improved anti-cd3 antibodies
WO2026150302A1 (en) 2025-01-09 2026-07-16 Novartis Ag Novel aav rep/cap encoding constructs
FR3171662A1 (fr) 2025-01-27 2026-07-31 Oncocellex Méthodes d’isolement des cellules tumorales circulantes en ciblant des antigènes glucidiques associés aux tumeurs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963355A (en) 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
WO1994018221A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
JPH08511417A (ja) 1993-04-09 1996-12-03 カタリティック アンティボディーズ，インコーポレイテッド 触媒抗体をコードする遺伝子の選択
WO1995027045A1 (en) 1994-03-30 1995-10-12 Igen, Inc. The isolation and production of catalytic antibodies using phage technology
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7598352B2 (en) * 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
EP1539941A4 (de) 2002-08-27 2006-11-29 Adzyme und deren verwendungen
WO2004029224A2 (en) * 2002-09-30 2004-04-08 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2

Also Published As

Publication number Publication date
EP1958962A2 (de) 2008-08-20
DE69839147D1 (de) 2008-04-03
DK0985039T3 (da) 2008-06-09
EP2380906A2 (de) 2011-10-26
US6673901B2 (en) 2004-01-06
ES2301198T3 (es) 2008-06-16
US20060257953A1 (en) 2006-11-16
JP2001500531A (ja) 2001-01-16
JP3614866B2 (ja) 2005-01-26
US20020019517A1 (en) 2002-02-14
EP0985039B1 (de) 2008-02-20
CA2293632C (en) 2011-11-29
WO1998056915A2 (en) 1998-12-17
WO1998056915A3 (en) 1999-03-04
US20120135516A1 (en) 2012-05-31
US20030170753A1 (en) 2003-09-11
US7078490B2 (en) 2006-07-18
US20100099168A1 (en) 2010-04-22
US8106162B2 (en) 2012-01-31
EP1958962A3 (de) 2013-05-01
US7858090B2 (en) 2010-12-28
US20030108948A1 (en) 2003-06-12
DE69839147T2 (de) 2009-02-19
US7153661B2 (en) 2006-12-26
AU7959698A (en) 1998-12-30
US20090270597A1 (en) 2009-10-29
US7119171B2 (en) 2006-10-10
US9127090B2 (en) 2015-09-08
US8062858B2 (en) 2011-11-22
US6462189B1 (en) 2002-10-08
US6703199B1 (en) 2004-03-09
US20030134386A1 (en) 2003-07-17
US20060240018A1 (en) 2006-10-26
US7981620B2 (en) 2011-07-19
EP0985039A2 (de) 2000-03-15
AU729035B2 (en) 2001-01-25
CA2293632A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
DK0985039T3 (da) Kunstige antistof-polypeptider
WO2002004523A3 (en) Artificial antibody polypeptides
Henderson et al. Amino acid sequence of human erythrocyte carbonic anhydrase C
DE3851289D1 (de) Verfahren zur Züchtung rekombinanter Zellen.
DE69434578D1 (de) Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren
ATE160584T1 (de) Rns-katalysator zur spaltung von spezifischen rns-sequenzen
NO883592D0 (no) Enzym.
WO2000006726A3 (en) Delta-related polypeptides
RU2005136013A (ru) Фосфодиэстераза 8а
ATE152124T1 (de) Wachstumsfaktor aus parenchymalen lebenszellen, dafür kodierendes gen, verfahren zur herstellung dieses faktors und transformanten
EP0821064A3 (de) Recombinanter Fructosyl Aminosäure-Oxidase
EP0494702A3 (en) Production of factor xiiia by gene technology
AU6661490A (en) Novel polypeptides, the DNA sequences allowing their expression, method of preparation, and utilization
DE3486350D1 (de) VERFAHREN ZUR ISOLIERUNG EINES PROTEINS AUS EINER DIESES PROTEIN ENTHALTENDEN MISCHUNG UNTER VERWENDUNG EINES KONFORMATIONSSPEZIFISCHEN ANTIKöRPERS.
DE69736389T8 (de) Proteine mit zellulase-aktivitäten und prozess für ihre herstellung
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
EP0333587A2 (de) Verfahren zur Reinigung und Isolierung carboxyl-endständiger Peptide
ATE102994T1 (de) Verfahren zur herstellung von proteinen.
ATE345382T1 (de) 2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
WO1999029724A3 (en) Dna encoding pasteurella multocida outer membrane protein
ATE445017T1 (de) Methode zur herstellung eines polypeptides, einer rna oder einer anderen verbindung in tumorgewebe
US6762041B2 (en) Method for isotope labeling of protein with enzyme
EP0289187A3 (de) Vinyl-substituierte Radiohalogen-Konjugate zur Markierung von Proteinen
WO1998003653A3 (fr) Procede de preparation d'organes de mammiferes non humains transgeniques en vue de leur transplantation chez l'homme, et sequences nucleotidiques pour la mise en oeuvre de ce procede
DE69634297D1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0985039

Country of ref document: EP